Nov 24, 2025 07:00AM Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 10, 2025 05:30PM Skye Bioscience (SKYE) Misses Q3 EPS by 32c

Oct 6, 2025 02:49PM Skye Bioscience (SKYE) PT Lowered to $4 at Citizens

Oct 6, 2025 01:05PM Skye Bioscience (SKYE) PT Lowered to $10 at Oppenheimer

Oct 6, 2025 12:11PM Craig-Hallum Downgrades Skye Bioscience (SKYE) to Hold

Oct 6, 2025 10:36AM Cantor Fitzgerald Downgrades Skye Bioscience (SKYE) to Neutral

Sep 23, 2025 07:38AM Piper Sandler on Skye Bioscience (SKYE): 'Own for Upcoming Phase II CBeyond Data on Nimacimab'

Sep 10, 2025 04:17AM Citizens JMP Reiterates Market Outperform Rating on Skye Bioscience (SKYE)

Sep 4, 2025 07:02AM Skye Bioscience reports preclinical obesity drug data ahead of phase 2

Aug 7, 2025 05:52PM Skye Bioscience (SKYE) Misses Q2 EPS by 44c

Jun 24, 2025 04:07AM Citizens JMP Reiterates Market Outperform Rating on Skye Bioscience (SKYE)

May 12, 2025 05:24AM Skye Bioscience (SKYE) PT Lowered to $17 at Oppenheimer

May 8, 2025 08:19PM Skye Bioscience (SKYE) Misses Q1 EPS by 28c

Apr 23, 2025 04:26AM Citizens JMP Reiterates Market Outperform Rating on Skye Bioscience (SKYE)

Apr 15, 2025 07:03AM Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Mar 21, 2025 06:40AM Cantor Fitzgerald Reiterates Overweight Rating on Skye Bioscience (SKYE)

Mar 21, 2025 04:43AM Citizens JMP Reiterates Market Outperform Rating on Skye Bioscience (SKYE)

Mar 20, 2025 04:10PM Skye Bioscience (SKYE) Misses Q4 EPS by 24c

Feb 28, 2025 01:09AM William Blair Starts Skye Bioscience (SKYE) at Outperform

Feb 5, 2025 10:05AM Cantor Fitzgerald Reiterates Overweight Rating on Skye Bioscience (SKYE)

Jan 13, 2025 07:02AM Skye Bioscience (SKYE) Provides 2025 Look Ahead and Year in Review

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Nov 14, 2024 07:08AM Skye Bioscience (SKYE) Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Oct 29, 2024 07:02AM Skye Bioscience (SKYE) Appoints Paul Grayson as Chairman

Sep 30, 2024 06:21AM Scotiabank Starts Skye Bioscience (SKYE) at Sector Outperform

Sep 23, 2024 07:01AM Skye Bioscience (SKYE) Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

Sep 23, 2024 07:01AM Skye Bioscience (SKYE) Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

Sep 10, 2024 02:29AM JMP Securities Starts Skye Bioscience (SKYE) at Market Outperform

Sep 9, 2024 07:28AM Piper Sandler Reiterates Overweight Rating on Skye Bioscience (SKYE)

Sep 3, 2024 07:01AM Skye Bioscience (SKYE) Appoints Puneet S. Arora as Chief Medical Officer

Aug 26, 2024 08:15AM Craig-Hallum Reiterates Buy Rating on Skye Bioscience (SKYE)

Aug 22, 2024 12:48PM Oppenheimer Reiterates Outperform Rating on Skye Bioscience (SKYE)

Aug 22, 2024 07:01AM Skye Bioscience (SKYE) Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab

Aug 12, 2024 03:36AM Skye Bioscience (SKYE) Tops Q2 EPS by 1c

Jul 24, 2024 07:31AM Skye Bioscience (SKYE) and Beacon Biosignals Collaborate to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial

Jul 11, 2024 07:02AM Skye Bioscience (SKYE) Appoints Clinical and Scientific Advisory Board to Support Development of Nimacimab

Jul 9, 2024 08:48AM Craig-Hallum Starts Skye Bioscience (SKYE) at Buy

Jul 3, 2024 07:00AM Skye Bioscience (SKYE) Appoints Karen Smith to its Board

Jul 1, 2024 07:03AM Skye Bioscience (SKYE) to Join Russell 2000 and Russell 3000

Jun 10, 2024 05:17PM Skye Bioscience (SKYE) PT Lowered to $21 at Oppenheimer

Jun 10, 2024 06:11AM Skye Bioscience (SKYE): Phase 2a clinical trial of SBI-100 OE in patients with POAG or ocular hypertension did not meet its primary endpoint